Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 I-Mab Explores TJM2 in Treating Severe COVID-19 Disease | Contract Pharma

What are you searching for?

Sign in
Breaking News

I-Mab Explores TJM2 in Treating Severe COVID-19 Disease

Clinical study will explore the potential of TJM2, a mAb against Cytokine Release Syndrome, which is an overreaction of the immune system caused by inflammation

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

I-Mab Biopharma is initiating the development of TJM2 (TJ003234) to treat cytokine storm in severe and critically ill patients with coronavirus disease (COVID-19). TJM2 is an I-Mab-discovered neutralizing antibody against human granulocyte-macrophage colony stimulating factor (GM-CSF), an important cytokine that plays a critical role in acute and chronic inflammation.

The development will start following the U.S. FDA acceptance of I-Mab’s IND application, and will commence initially in the U.S. with plans to expand into other hard-hit countries.

Cytokine storm is characterized by surge of high levels of circulating inflammatory cytokines, and is an overreaction of the immune system under the conditions, such as CAR-T therapy [1] and patients infected with SARS-CoV-2. Recent studies show that high levels of GM-CSF, along with a few other cytokines, are critically associated with severe clinical complications in COVID-19 patients.  

The company has successfully completed a Phase I study of TJM2 in the U.S., in which TJM2 exhibited favorable safety, tolerability, PK/PD, and immunogenicity profiles. The results from the planned COVID-19 study will also be used to further evaluate the potential therapeutic role of TJM2 in reducing or preventing cytokine storm and neurotoxicity associated with CAR-T therapy.

According to the WHO, as of March 12, 2020, there were 125,048 confirmed cases and 4,613 deaths of COVID-19 globally.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters